Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Arena Reapplying for Approval of Lorcaserin

By Drug Discovery Trends Editor | December 22, 2010

SAN DIEGO (AP) – Arena Pharmaceuticals Inc. said it plans to again ask the Food and Drug Administration to approve its experimental weight-loss drug lorcaserin by the end of 2011, following the agency’s recent rejection over safety concerns.

Lorcaserin, being developed with Eisai Inc., is Arena’s most advanced clinical product and a major potential revenue producer. The company made the announcement after it completed a review meeting with the agency. It said it will continue to “refine elements” of its plan to again ask for approval.

In October, the agency rejected lorcaserin and potential competitor Vivus Inc.’s Qnexa because of safety concerns. Both the drugs had been given negative recommendations by an FDA panel of experts prior to the agency’s rejection. Specifically, the agency was concerned that about tumors seen in rats in early-stage lorcaserin testing, one of the factors that Arena Pharmaceuticals said the FDA had cited in a letter responding to the company’s application. In addition, the FDA has said the drug was only marginally effective in overweight and obese individuals without type 2 diabetes.

Meanwhile, competitor Vivus plans on meeting with the agency in January and has already asked European regulators to approve Qnexa. The FDA rejected the drug initially because of concerns over potential heart problems and birth defects.

So far, Orexigen Therapeutics Inc.’s Contrave is the only weight-loss drug to gain a positive recommendation from a panel of FDA experts. The FDA is scheduled to make a decision on the drug by Jan. 31.

Date: December 22, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50